|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-2.62/-2.31
|
企業價值
1.62B
|
資產負債 |
每股賬面淨值
4.30
|
現金流量 |
現金流量率
--
|
損益表 |
收益
0
|
每股收益
0.16
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/10/31 19:39 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. |